CTIS2024-514746-36-00招募中1 期
OMTX705-001
Oncomatryx Biopharma S.L.0 个研究点目标入组 120 人开始时间: 2024年6月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Safety, pharmacokinetics, and preliminary efficacy of AMX-500 in metastatic castration resistant prostate cancer (mCRPCCTIS2023-503495-24-00Sanofi-Aventis Recherche & Developpement271
进行中（未招募）
1 期
A phase 1/phase 2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high-risk smoldering multiple myeloma or multiple myeloma and evidence of measurable disease = 1 line of treatment.multiple myelomaCTIS2022-502275-39-00Oslo University Hospital Hf20
招募中
1 期
A study of STX-721 in participants with non-small cell lung cancer with certain mutationsocally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non-small cell lung cancer NOS Class: 10029104CTIS2023-506759-51-00Scorpion Therapeutics Inc.112
招募中
1 期
A phase I of TG6050 in the treatment of patients with metastatic lung canceron-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864CTIS2024-513093-22-00Transgene36
进行中（未招募）
1 期
MK-7602 Multiple Ascending Dose Study in Healthy ParticipantsMedDRA version: 20.0Level: PTClassification code: 10025487Term: Malaria Class: 100000004862MalariaCTIS2023-503738-36-00Merck Sharp & Dohme LLC40